Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemosensitivity monitoring of first-line antimalarial drugs in children with uncomplicated falciparum malaria in Burkina Faso
PACTR202405899935406Phase 4Recruiting
- Sponsor
- Secrétariat Permanent pour l'Élimination du Paludisme
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artemether + lumefantrine, dihydroartemisinin + piperaquine and artesunate + pyronaridine in Malaria (3 arms), sponsored by Secrétariat Permanent pour l'Élimination du Paludisme. Primary endpoints: Early Treatment Failure, Late Treatment Failure and 2 more. Started May 2024; status: recruiting.
02
Drugs
artemether + lumefantrinedihydroartemisinin + piperaquineartesunate + pyronaridine
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR202405899935406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202405899935406.